Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiere in Wet AMD
NCT03668054Phase 3Completed
- Sponsor
- Laboratorio Elea Phoenix S.A.
- Start
- Feb 2017
- Primary completion
- May 2018
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in exudative macular degeneration, sponsored by Laboratorio Elea Phoenix S.A. Primary endpoint: Number of participants with treatment-related adverse events at 6 months. Started Feb 2017; status: completed.
02
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03668054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03668054.